Antagonists of PD-1 and PD-L1 in cancer treatment

EJ Lipson, PM Forde, HJ Hammers, LA Emens… - Seminars in …, 2015 - Elsevier
The PD-1 pathway, comprising the immune cell co-receptor Programmed Death 1 (PD-1)
and its ligands, PD-L1 (B7-H1) and PD-L2 (B7-DC), mediates local immunosuppression in
the tumor microenvironment. Drugs designed to block PD-1 or PD-L1 “release the brakes”
on anti-tumor immunity and have demonstrated clinical activity in several types of advanced
cancers, validating this pathway as a target for cancer therapy. Two such drugs have
recently been approved to treat melanoma and lung cancers, and regulatory approvals in …